Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implications for treatment of infants

Leukemia

Volumn 12, Issue 9, 1998, Pages 1344-1348

  Pieters, R ^a   Den Boer, M L ^a   Durian, M ^a   Janka, G ^c   Schmiegelow, K ^d   Kaspers, G J L ^a   Van Wering, E R ^b   Veerman, A J P ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c COALL Study Group ^*  (Germany)

^d Rigshospitalet   (Denmark)

Author keywords

Acute lymphoblastic leukemia; Age; Cytosine arabinoside; Drug resistance; Infant; MLL; T ALL

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

EID: 0031717981     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401129     Document Type: Article

References (24)

1. Pui C-H. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
2. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
3. Reaman G, Zeltzer P, Bleyer A, Amendola B, Level C, Sather H, Hammond D. Acute lymphoblastic leukemia in infants less than 1 year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3: 1513-1521.
4. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials report from the Medical Research Council Working Party on childhood leukaemia. Leukemia 1994; 8: 1275-1279.
5. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10: 372-377.
6. Basso G, Rondelli R, Covezzoli A, Putti MC. The role of immunophenotype in acute lymphoblastic leukemia of infant age. Leuk Lymphoma 1994; 15: 51-60.
7. Cimino G, Rapanotti MC, Rivolta A, Lo Coco F, D'Arcangelo E, Rondelli R, Basso G, Barisone E, Rosanda C, Santostasi T, Canaani E, Masera G, Mandelli F, Biondi A. Prognostic relevance of ALL-1 gene rearrangement in infant leukemias. Leukemia 1995; 9: 391-395.
8. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G, Thyss A, Robert A, Mazingue F, Souillet G, Philippe N, Solbu G, Suciu S, Otten J. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994; 86: 284-290.
9. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
10. Hilden JM, Frestedt JL, Moore RO, Heerema NA, Arthur DC, Reaman GH, Kersey JH. Molecular analysis of infant acute lymphoblastic leukemia: MLL rearrangement and reverse-transcriptase polymerase chain reaction for t(4;11)(q21;q23). Blood 1995; 86: 3876-3882.
11. Pui C-H, Ribeiro RC, Campana D, Raimondi SC, Hancock ML, Behm FG, Sandlund JT, Rivera GK, Evans WE, Crist WM, Krance R. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 1996; 10: 952-956.
12. Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER, Veerman AJP. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
13. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 1995; 19: 407-417.
14. Pieters R, Loonen AH, Huismans DR et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
15. Pieters R, Huismans DR, Leyva A, Veerman AJP. Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988; 41: 323-332.
16. Pieters R, Huismans DR, Leyva A, Veerman AJP. Comparison of a rapid automated tetrazolium based (MTT) assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 1989; 59: 217-220.
17. Kaspers GJ, Pieters R, van Zantwyk CH, de Laat PAJM, de Waal FC, van Wering ER, Veerman AJP. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-174.
18. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Doesvan den Berg A, van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
19. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959-2965.
20. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk CH, Smets LA, van Wering ER, van der Does-van den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
21. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DC, Tarbell NJ, Sallan SE. Intensified therapy for infants with acute lymphoblastic leukemia. Results from the Dana-Farber Cancer Institute consortium. Cancer 1997; 80: 2285-2295.
22. Maung ZT, Reid MM, Matheson E, Taylor PRA, Proctor SJ, Hall AC. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br J Haematol 1995; 91: 93-100.
23. Klumper E, Pieters R, Veerman AJP et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
24. Pieters R, Klumper E, Kaspers GJL, Veerman AJP. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Hematol Oncol 1997; 25: 11-26.